These studies showed that robust KRAS activation and FGFR2 fusion proteins inhibit proliferation and growth in normal hepatobiliary cells, and the combination with suppression/depletion of tumor-suppressor genes, such as Ink4a/Arf or TP53, is required for CCA tumorigenesis. This evidence concerns the gene FGFR2 and cholangiocarcinoma.